Skip to main content

Table 6 Effect of hypertonic saline and furosemide on hemodynamic variables in a randomized, cross-over study of 24 healthy subjects

From: Effect of 3% saline and furosemide on biomarkers of kidney injury and renal tubular function and GFR in healthy subjects – a randomized controlled trial

Period Baseline Hypertonic saline infusion Post hypertonic saline infusion  
  0–90 min 90–150 min 150–180 min 180–210 min 210–240 min 240–300 min P (GLM within)
SBP (mmHg)
 Placebo 118 ± 9 118 ± 10 117 ± 9 119 ± 10 117 ± 10 120 ± 9 0.001
 Furosemide 117 ± 7 120 ± 13 114 ± 6* 111 ± 8* 113 ± 8* 116 ± 8
P (GLM between) 0.202  
DBP (mmHg)
 Placebo 68 ± 7 67 ± 7 64 ± 8* 67 ± 7* 66 ± 6* 67 ± 8 0.003
 Furosemide 68 ± 6 69 ± 7 67 ± 8 66 ± 6* 67 ± 7* 66 ± 6*
P (GLM between) 0.740  
HR (beats/min)
 Placebo 62 ± 10 66 ± 11* 63 ± 11 64 ± 10* 62 ± 10 64 ± 11* 0.354
 Furosemide 61 ± 8 65 ± 10* 63 ± 9* 63 ± 8* 64 ± 10* 64 ± 10*
P (GLM between) 0.875  
  1. SBP, DBP Systolic and diastolic blood pressure, HR heart rate, cSBP, cDBP central systolic and diastolic blood pressure, AI augmentation index VR vascular resistance. Blood pressure was measured every 30 min in the 90 min baseline period, once after 60 min of hypertonic infusion, and every 30 min 90 min after hypertonic saline infusion and once 150 min after cessation of hypertonic saline infusion. Data from four baseline measurements are pooled and shown as one period. Data are presented as means ± SD. Statistics are performed with a general linear model (GLM) or paired t-test. Statistically significant difference from baseline: * = p < 0.05